secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001104659-26-044025
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx reports positive 3-year Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia
--------------------------------------------------------------------------------

- 62% of patients had ≥10-point XQ improvement at 36 months; average 17-point improvement maintained from 12 months.
- Unstimulated saliva flow normalized to average 0.36 mL/min at 12 months, maintained at 0.34 mL/min at 36 months.
- No dose-limiting toxicity or treatment-related serious adverse events; well tolerated at all doses.
- Company estimates peak global revenue potential of $3.7B, U.S. peak of $2.0B, targeting ~165,000 U.S. patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000110465926044025/0001104659-26-044025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000110465926044025/mgtx-20260416x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-044025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer